James C Leadingham, O.d., Psc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 112 Vinson Blvd, Louisa, KY 41230 Phone: 606-638-4731 Fax: 606-638-3523 |
Dr. James C Leadingham, O.D., PSC Optometrist Medicare: Not Enrolled in Medicare Practice Location: 112 Vinson Blvd, Louisa, KY 41230 Phone: 606-638-4731 Fax: 606-638-3523 |
Dr. Joseph Ray Bowling, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 112 S Vinson Blvd, Louisa, KY 41169 Phone: 606-638-4731 |
Louisa Eye Care, Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 112 S Vinson Ave, Louisa, KY 41230 Phone: 606-638-4731 Fax: 606-638-3523 |
News Archive
Computational estimates of apolipoprotein B and apolipoprotein A1 can be used as reliable markers for atherosclerosis, report researchers.
The treatment of diabetes was revolutionized in 1922 when insulin was isolated from dogs. Since then, significant advances in human medicine have made diabetes more manageable for patients. Now, human medicine has returned the favor and used these advances to help dogs with diabetes. A University of Missouri researcher is using a continuous glucose monitoring device - commonly used in humans with diabetes - to help treat dogs and other animals. The device, which provides a detailed glucose picture of an animal over several days, will help pet owners manage their pets' diabetes.
Although viruses technically may not be alive, their contribution to the dynamic web of life is undeniable. A new book, published by ASM Press, focuses on the role that viruses have played and continue to play in the evolution of life.
Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA's HIV resistance interpretation system.
A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.
› Verified 7 days ago